Synopsis Osteoporosis is a predominant health problem in females, caused by aging. The wide and common use of glucocorticoids to treat various diverse conditions often results in Glucocorticoid-Induced Osteoporosis (GIO), which has become a serious clinical concern worldwide. In this study, the primary aim was to characterize the effects of alendronate on bone mineral density (BMD) and to assess the risks of adverse reactions associated with alendronate treatment. The present study evaluates both the efficacy and safety of alendronate in the treatment of Glucocorticoid-Induced Osteoporosis . This week’s “ MED FACT ” discusses the clinical trial from The Medicine Journal, “ Effects of alendronate for the treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials”.
Authors : Wang. Y.K.; et. al. Key Takeaways: Alendronate significantly increases the…
